PURPOSE: The aim of this chart review of adult patients treated for acute lymphoblastic leukemia (ALL) with total body irradiation (TBI) was to evaluate early and late toxicity and long-term outcome. PATIENTS AND METHODS: A total of 110 adult patients (34 ± 12 years) with ALL underwent TBI (6 fractions of 2 Gy for a total of 12 Gy) as a part of the treatment regimen before transplantation. Treatment-related toxicity, mortality, and hematologic outcome are reported. RESULTS: Mean follow-up was 70 months. The 2- and 5-year leukemia-free survival rates were 78 and 72%, respectively. In all, 29% (32/110) patients suffered from medullary recurrence after a median time of 7 months. Gender was the only statistically significant prognostic factor in terms of overall survival in favor of female patients. Treatment-related mortality and overall survival after 2 and 5 years were 16 and 22%, and 60 and 52.7%, respectively. The most frequent late reaction wascGVHD of the skin (n = 33, 30%). In addition, 15.5% (17/110 patients) suffered pulmonary symptoms, and 6 patients developed lung fibrosis. Eyes were frequently affected by the radiation (31/110 = 28%); 12 of 110 patients (11%) presented with symptoms from osteoporosis, 5 of 110 patients (4.5%) developed hypothyreosis and 2 patients diabetes mellitus. Of the male patients, 11% reported erectile dysfunction or loss of libido, while 2 of 36 women reported menopausal syndrome at the mean time of 28 months after treatment with requirement for substitution. No women became pregnant after treatment. No acute or late cardiac toxicities were documented in our patients. No secondary malignancies were documented. CONCLUSION: Although hematologic outcome was in the upper range of that reported in the literature, treatment-related mortality (TRM) and medullary recurrences remain a challenge. Sophisticated radiation techniques allow for decreasing toxicity to certain organs and/or dose escalation to the bone marrow in highly selected patients in order to improve therapeutic breadth.
PURPOSE: The aim of this chart review of adult patients treated for acute lymphoblastic leukemia (ALL) with total body irradiation (TBI) was to evaluate early and late toxicity and long-term outcome. PATIENTS AND METHODS: A total of 110 adult patients (34 ± 12 years) with ALL underwent TBI (6 fractions of 2 Gy for a total of 12 Gy) as a part of the treatment regimen before transplantation. Treatment-related toxicity, mortality, and hematologic outcome are reported. RESULTS: Mean follow-up was 70 months. The 2- and 5-year leukemia-free survival rates were 78 and 72%, respectively. In all, 29% (32/110) patients suffered from medullary recurrence after a median time of 7 months. Gender was the only statistically significant prognostic factor in terms of overall survival in favor of female patients. Treatment-related mortality and overall survival after 2 and 5 years were 16 and 22%, and 60 and 52.7%, respectively. The most frequent late reaction wascGVHD of the skin (n = 33, 30%). In addition, 15.5% (17/110 patients) suffered pulmonary symptoms, and 6 patients developed lung fibrosis. Eyes were frequently affected by the radiation (31/110 = 28%); 12 of 110 patients (11%) presented with symptoms from osteoporosis, 5 of 110 patients (4.5%) developed hypothyreosis and 2 patientsdiabetes mellitus. Of the male patients, 11% reported erectile dysfunction or loss of libido, while 2 of 36 women reported menopausal syndrome at the mean time of 28 months after treatment with requirement for substitution. No women became pregnant after treatment. No acute or late cardiac toxicities were documented in our patients. No secondary malignancies were documented. CONCLUSION: Although hematologic outcome was in the upper range of that reported in the literature, treatment-related mortality (TRM) and medullary recurrences remain a challenge. Sophisticated radiation techniques allow for decreasing toxicity to certain organs and/or dose escalation to the bone marrow in highly selected patients in order to improve therapeutic breadth.
Authors: Chris R Kelsey; Mitchell E Horwitz; Junzo P Chino; Oana Craciunescu; Beverly Steffey; Rodney J Folz; Nelson J Chao; David A Rizzieri; Lawrence B Marks Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-06 Impact factor: 7.038
Authors: Michael B Tomblyn; Mukta Arora; K Scott Baker; Bruce R Blazar; Claudio G Brunstein; Linda J Burns; Todd E DeFor; Kathryn E Dusenbery; Dan S Kaufman; John H Kersey; Margaret L MacMillan; Philip B McGlave; Jeffrey S Miller; Paul J Orchard; Arne Slungaard; Marcie R Tomblyn; Gregory M Vercellotti; Michael R Verneris; John E Wagner; Daniel J Weisdorf Journal: J Clin Oncol Date: 2009-07-06 Impact factor: 44.544
Authors: T De Witte; B Awwad; J Boezeman; A Schattenberg; P Muus; J Raemaekers; F Preijers; P Strijckmans; C Haanen Journal: Bone Marrow Transplant Date: 1994-11 Impact factor: 5.483
Authors: Irina Bronova; Brett Smith; Bulent Aydogan; Ralph R Weichselbaum; Kiran Vemuri; Katalin Erdelyi; Alex Makriyannis; Pal Pacher; Evgeny V Berdyshev Journal: Am J Respir Cell Mol Biol Date: 2015-10 Impact factor: 6.914
Authors: Michael Oertel; Jonas Martel; Jan-Henrik Mikesch; Sergiu Scobioala; Christian Reicherts; Kai Kröger; Georg Lenz; Matthias Stelljes; Hans Theodor Eich Journal: Cancers (Basel) Date: 2021-11-11 Impact factor: 6.639
Authors: Petra M Härtl; Marius Treutwein; Matthias G Hautmann; Manuel März; Fabian Pohl; Oliver Kölbl; Barbara Dobler Journal: Radiat Oncol Date: 2016-06-10 Impact factor: 3.481
Authors: Sultan Altouri; Mitchell Sabloff; David Allan; Harry Atkins; Lothar Huebsch; Dawn Maze; Rajiv Samant; Christopher Bredeson Journal: Case Rep Hematol Date: 2016-11-13
Authors: Andreas Springer; Josef Hammer; Erwin Winkler; Christine Track; Roswitha Huppert; Alexandra Böhm; Hedwig Kasparu; Ansgar Weltermann; Gregor Aschauer; Andreas L Petzer; Ernst Putz; Alexander Altenburger; Rainer Gruber; Karin Moser; Karin Wiesauer; Hans Geinitz Journal: Radiat Oncol Date: 2016-03-22 Impact factor: 3.481